• +1-646-491-9876
    • +91-20-67278686

    Search

    Histone Deacetylase 4-Pipeline Review H1 2017

    Histone Deacetylase 4-Pipeline Review H1 2017

    • Report Code ID: RW0001834423
    • Category Pharmaceuticals
    • No. of Pages 60
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2017

    Summary

    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. It acts via the formation of large multiprotein complexes.

    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Ophthalmology which include indications Breast Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Bladder Cancer, Congestive Heart Failure (Heart Failure) , Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) , Leiomyosarcoma, Liver Cancer, Lung Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelofibrosis, Post-Polycythemia Vera Myelofibrosis (PPV-MF) and Retinitis Pigmentosa (Retinitis) .

    The latest report Histone Deacetylase 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)
    - The report reviews Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Overview
    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
    4SC AG
    HitGen LTD
    MEI Pharma Inc
    Mirati Therapeutics Inc
    Sigma-Tau SpA
    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Drug Profiles
    Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HG-3001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mocetinostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pracinostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    resminostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ST-3595 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Dormant Products
    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Discontinued Products
    Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Product Development Milestones
    Featured News & Press Releases
    May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
    Jan 24, 2017: Overall survival benefit for resminostat in first-line liver cancer study subgroup
    Jan 05, 2017: Mirati Therapeutics Provides Update On Mocetinostat Program
    Dec 16, 2016: First patient enrolled in pivotal RESMAIN study of resminostat in CTCL
    Dec 05, 2016: Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
    Nov 03, 2016: Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting
    Aug 01, 2016: MEI Pharmas Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
    Jun 05, 2016: Mirati Therapeutics Provides Update On Mocetinostat Program
    May 27, 2016: 4SC provides headline results from Yakult Honsha's Phase II trial of resminostat in combination with sorafenib as first line therapy in liver cancer
    May 10, 2016: Subgroup analysis suggests survival benefit in patients with advanced liver cancer treated with resminostat
    Mar 24, 2016: Mirati Therapeutics To Present Mocetinostat Preclinical Data At 2016 American Association For Cancer Research Annual Meeting
    Feb 24, 2016: FDA approves IND application for resminostat in liver cancer
    Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study
    Oct 06, 2015: MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting
    Sep 30, 2015: 4SC Receives Funding From The Eurostars Programme For Further Research Of Its Anti-Cancer Agent Resminostat With An Epigenetic Mode Of Action
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by 4SC AG, H1 2017
    Pipeline by HitGen LTD, H1 2017
    Pipeline by MEI Pharma Inc, H1 2017
    Pipeline by Mirati Therapeutics Inc, H1 2017
    Pipeline by Sigma-Tau SpA, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    4SC AG
    HitGen LTD
    MEI Pharma Inc
    Mirati Therapeutics Inc
    Sigma-Tau SpA

    Request for Sample

    Report Url https://www.reportsweb.com//histone-deacetylase-4-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//histone-deacetylase-4-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//histone-deacetylase-4-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments